Perspective Therapeutics (NYSEAMERICAN:CATX) Reaches New 1-Year High at $1.90

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX)’s share price hit a new 52-week high on Wednesday . The stock traded as high as 1.90 and last traded at 1.84, with a volume of 3917500 shares. The stock had previously closed at 1.83.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Cantor Fitzgerald initiated coverage on Perspective Therapeutics in a report on Thursday. They issued an “overweight” rating for the company. Oppenheimer reiterated an “outperform” rating and issued a $1.50 price objective (up from $1.20) on shares of Perspective Therapeutics in a research report on Monday, April 1st. Lifesci Capital restated an “outperform” rating on shares of Perspective Therapeutics in a research report on Monday. Finally, B. Riley raised their price target on Perspective Therapeutics from $1.20 to $1.70 and gave the company a “buy” rating in a report on Tuesday, April 9th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of 1.53.

Perspective Therapeutics Stock Performance

The firm has a market capitalization of $1.06 billion, a PE ratio of -18.00 and a beta of 1.43. The company has a quick ratio of 1.07, a current ratio of 1.07 and a debt-to-equity ratio of 0.02.

Insider Transactions at Perspective Therapeutics

In other Perspective Therapeutics news, major shareholder Lantheus Alpha Therapy, Llc acquired 60,431,039 shares of Perspective Therapeutics stock in a transaction dated Wednesday, March 6th. The stock was bought at an average cost of 0.95 per share, for a total transaction of 57,409,487.05. Following the purchase, the insider now directly owns 116,773,394 shares in the company, valued at approximately 110,934,724.30. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. 3.52% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Perspective Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of CATX. ZWJ Investment Counsel Inc. acquired a new stake in Perspective Therapeutics during the first quarter worth approximately $26,000. Simplicity Wealth LLC acquired a new stake in Perspective Therapeutics during the 1st quarter worth approximately $40,000. Bleakley Financial Group LLC bought a new stake in Perspective Therapeutics in the 1st quarter valued at $40,000. Taylor & Morgan Wealth Management LLC grew its holdings in Perspective Therapeutics by 8.7% in the 4th quarter. Taylor & Morgan Wealth Management LLC now owns 625,000 shares of the company’s stock valued at $251,000 after buying an additional 50,000 shares in the last quarter. Finally, RIA Advisory Group LLC increased its position in Perspective Therapeutics by 1,313.4% during the 1st quarter. RIA Advisory Group LLC now owns 106,853 shares of the company’s stock worth $127,000 after buying an additional 99,293 shares during the period. Institutional investors own 54.66% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.